- Eli Lilly and Novo Nordisk have both developed anti-obesity drugs, intensifying competition in the weight loss market.
- Eli Lilly raised Zepbound prices in the U.K. and plans to follow price hikes across Europe, while Novo Nordisk received a drug price reduction letter amid Trump administration pressure.
- The FDA has ruled on copycat drugs produced in China, while Novo Nordisk navigates price reduction demands from Trump and leadership changes.
- Trump administration announced FDA coverage changes regarding Chinese suppliers who are not registered.
The Trump administration is leading to FDA job cuts, while Elon Musk spearheaded the Department of Government Efficiency, and China has surpassed the US in clinical trial volume.
2 reports, 2 independent
Updated Jul 31
Gone quiet
- Reports
- 2
- Developments
- 2
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
The Trump administration is leading to FDA job cuts, while Elon Musk spearheaded the Department of Government Efficiency, and China has surpassed the US in clinical trial volume.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.- Trump administration proposes new approaches to stretch FDA resources, involving Michael Rogers.Sub-event
Trump administration actions causing FDA cuts, Musk leadership, and China's rise in clinical trials.1 source
Keep exploring
Part of
Trump administration announced FDA coverage changes regarding Chinese suppliers who are not registered.Also in this story
- Ingredients sourced from China are facing compliance issues due to new tariffs and required ingredient and labeling changes to meet FDA standards.
- The FDA is currently evaluating data needed for alternate dosing licenses, while sales in China declined significantly in 2025.
The entities involved
- FDA
-
Donald Trump
American businessman and politician (born 1946), President of the United States (2017–2021; since 2025)
-
China
cultural region, ancient civilization, and nation in East Asia; mostly refers to the People's Republic of China in political situation and rarely refers to the Republic of China
Related events
- The US administration rejected a proposed FDA-style central AI regulator while acknowledging the need to compete with China in the AI race.
- NIH cuts budgets and personnel, impacting funded research leading to FDA-approved treatments.
- The FDA is facing public scrutiny due to oversight failures, leading to the introduction of new legislation targeting agency shortcomings.
- Trump administration slashes food safety enforcement and reduces workforce at FDA, FSIS, and CDC.